Literature DB >> 23088212

Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.

Y Chen1, Y Lu, Y Wang, H Yang, Y Xia, M Chen, H Song, T Li, D Li, J Wang, S Li, J Wang.   

Abstract

A consensus treatment strategy for esophageal squamous cell carcinoma (ESCC) patients who recur after definitive radiochemotherapy/radiotherapy has not been established. This study compared the outcomes in ESCC patients who underwent salvage surgery, salvage chemoradiation (CRT) or best supportive care (BSC) for local recurrence. Ninety-five patients with clinical stage I to III ESCC who had completely responded to the initial definitive radiochemotherapy or radiotherapy alone and developed local recurrence were enrolled in this study. Fifty-one of them received salvage esophagectomy, and R0 resection was performed in 41 patients, 36 underwent salvage CRT, and the remaining eight patients received BSC only. The 5-year overall survival was 4.6% for the 87 patients receiving salvage surgery or CRT, while all patients in the BSC group died within 12.0 months, the difference was statistically significant (P = 0.018). The 1-, 3-, 5-year survival rates in the salvage surgery and salvage CRT groups were 45.1%, 20.0%, 6.9% and 51.7%, 12.2%, 3.1%, respectively, there was no difference of overall survival between the two groups (P = 0.697). Patients also presented with lymph node relapse had inferior survival compared to those with isolated local tumor recurrence after salvage therapy. In the salvage surgery group, infections occurred in eight patients, and three developed anastomotic leakage. In the salvage CRT group, grade 2-4 esophagitis and radiation pneumonitis was observed in 19 and 3 patients, respectively. Seven patients (19.4%) developed esophagotracheal fistula or esophageal perforation. This study of salvage CRT versus salvage surgery for recurrent ESCC after definitive radiochemotherapy or radiotherapy alone did not demonstrate a statistically significant survival difference, but the frequency of complications including esophagotracheal fistula and esophageal perforation following salvage CRT was high.
© 2012 Copyright the Authors. Journal compilation © 2012, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Keywords:  esophageal cancer; prognosis; recurrence; salvage therapy; squamous cell carcinoma

Mesh:

Substances:

Year:  2012        PMID: 23088212     DOI: 10.1111/j.1442-2050.2012.01440.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  21 in total

1.  Re-irradiation of locoregional esophageal cancer recurrence following definitive chemoradiotherapy: A report of 6 cases.

Authors:  Atsuto Katano; Hideomi Yamashita; Keiichi Nakagawa
Journal:  Mol Clin Oncol       Date:  2017-08-18

2.  [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].

Authors:  T Schmidt; L Sisic; F Sterzing; G-M Haag; R Kunzmann; L Grenacher; W Weichert; D Jäger; M W Büchler; K Ott
Journal:  Chirurg       Date:  2015-10       Impact factor: 0.955

3.  Expression of basic fibroblast growth factor, CD31, and α-smooth muscle actin and esophageal cancer recurrence after definitive chemoradiation.

Authors:  Yongshun Chen; Xiaohong Li; Haijun Yang; Yubing Xia; Leiming Guo; Xiaoyuan Wu; Chunyu He; You Lu
Journal:  Tumour Biol       Date:  2014-04-29

Review 4.  [Limitations of surgery for cancer of the upper gastrointestinal tract].

Authors:  E Karakas; C Oetzmann von Sochaczewski; T Haist; M Pauthner; D Lorenz
Journal:  Chirurg       Date:  2014-03       Impact factor: 0.955

5.  Different strategy of salvage esophagectomy between residual and recurrent esophageal cancer after definitive chemoradiotherapy.

Authors:  Yusuke Taniyama; Tadashi Sakurai; Takahiro Heishi; Hiroshi Okamoto; Chiaki Sato; Shota Maruyama; Yu Onodera; Hirotaka Ishida; Michiaki Unno; Takashi Kamei
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

6.  Definitive re-irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status.

Authors:  Daniel W Kim; Sana Raoof; Nayan Lamba; Grace Lee; Danielle S Bitterman; Amandeep R Mahal; Nina N Sanford; Miranda B Lam; Harvey J Mamon
Journal:  Mol Clin Oncol       Date:  2020-05-11

7.  Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2.

Authors:  Yuko Kitagawa; Takashi Uno; Tsuneo Oyama; Ken Kato; Hiroyuki Kato; Hirofumi Kawakubo; Osamu Kawamura; Motoyasu Kusano; Hiroyuki Kuwano; Hiroya Takeuchi; Yasushi Toh; Yuichiro Doki; Yoshio Naomoto; Kenji Nemoto; Eisuke Booka; Hisahiro Matsubara; Tatsuya Miyazaki; Manabu Muto; Akio Yanagisawa; Masahiro Yoshida
Journal:  Esophagus       Date:  2018-08-31       Impact factor: 3.671

8.  Clinical analyses on salvage lymphadenectomy through cervical incision for patients with cervical and cervicothoracic recurrences after esophagectomy.

Authors:  Dong Lin; Shujun Jiang; Longfei Ma; Hong Hu; Ting Ye; Longlong Shao; Zuodong Song; Jiaqing Xiang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

9.  A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.

Authors:  Xun Wu; Xingsheng Hu; Junru Chen; Lang He
Journal:  Radiat Oncol       Date:  2021-06-08       Impact factor: 3.481

10.  Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis.

Authors:  Liang Hong; Yun-Xia Huang; Qing-Yang Zhuang; Xue-Qing Zhang; Li-Rui Tang; Kai-Xin Du; Xiao-Yi Lin; Bu-Hong Zheng; Shao-Li Cai; Jun-Xin Wu; Jin-Luan Li
Journal:  Radiat Oncol       Date:  2018-09-10       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.